Security Snapshot

TAKEDA PHARMACEUTICAL CO LTD - SPONSORED ADS (TAK) Institutional Ownership

CUSIP: 874060205

13F Institutional Holders and Ownership History from Q1 2014 to Q2 2026

Latest Period

Q1 2026

Institutions Reporting

358

Shares (Excl. Options)

98,217,535

Price

$18.52

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
+14,496,760
Value change
+$279,445,106
Number of holders
358
Issuer context Names, identifiers, and filing context for this profile. 1 identity field
SEC-reported price per share
$16.03
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • TAK - TAKEDA PHARMACEUTICAL CO LTD - SPONSORED ADS is tracked under CUSIP 874060205.
  • 358 institutions reported positions in Q1 2026.
  • Schedule 13D/13G significant owner rows are not currently available.

Change

  • Holder count moved from 358 to 6 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from $1,818,351,823 to $924,820.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 358 institutions filings for Q1 2026.

Open SEC evidence

Security key

874060205

Latest holder period

Q1 2026

13F holders

358

13D/G owners

0

CIK / CUSIP context first

As of 31 Mar 2026, 358 institutional investors reported holding 98,217,535 shares of TAKEDA PHARMACEUTICAL CO LTD - SPONSORED ADS (TAK).

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
50
Latest
Q1 2026
Rows shown
1-25 of 50
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q2 57,693 $924,820 +$96,628 $16.03 6
2026 Q1 98,217,535 $1,818,351,823 +$279,445,106 $18.52 358
2025 Q4 83,746,535 $1,305,638,001 -$26,106,900 $15.59 347
2025 Q3 85,210,658 $1,247,493,378 +$106,067,914 $14.64 324
2025 Q2 77,806,509 $1,202,785,823 +$106,862,917 $15.46 307
2025 Q1 71,086,493 $1,057,034,943 -$156,054 $14.87 300
2024 Q4 72,039,413 $953,847,647 -$55,374,045 $13.24 295
2024 Q3 71,553,169 $1,015,380,211 +$20,521,956 $14.22 295
2024 Q2 72,061,993 $940,730,985 -$86,515,519 $12.94 281
2024 Q1 78,179,293 $1,087,229,460 -$73,198,839 $13.89 310
2023 Q4 83,396,860 $1,190,086,769 +$34,664,126 $14.27 302
2023 Q3 80,437,115 $1,242,500,598 -$66,352,882 $15.47 310
2023 Q2 84,017,983 $1,320,003,579 -$935,677 $15.71 308
2023 Q1 82,262,152 $1,355,589,943 +$248,962,456 $16.48 296
2022 Q4 68,069,757 $1,063,701,562 +$48,470,698 $15.60 278
2022 Q3 63,905,792 $829,049,514 +$90,138,783 $12.97 258
2022 Q2 56,978,507 $799,748,914 +$66,260,391 $14.04 258
2022 Q1 56,159,628 $802,855,152 -$261,335,589 $14.32 265
2021 Q4 75,991,152 $1,037,422,048 -$299,110,798 $13.63 271
2021 Q3 91,971,894 $1,505,006,212 -$51,986,093 $16.38 274
2021 Q2 94,938,677 $1,598,252,322 -$223,745,245 $16.83 287
2021 Q1 107,728,479 $1,962,038,029 -$1,144,218 $18.26 300
2020 Q4 108,743,491 $1,978,272,193 +$47,411,066 $18.20 291
2020 Q3 107,411,892 $1,906,842,183 -$74,858,671 $17.84 296
2020 Q2 111,608,181 $2,000,687,993 -$67,870,563 $17.93 291
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .